Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases
Autoimmune blistering diseases (AIBDs) comprise a group of rare conditions marked by autoantibodies that specifically target intercellular adhesion molecules. Despite the progress made in comprehending the disease and the increasing number of treatment options available, there is still no definitive...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1243581/full |
| _version_ | 1797674103978590208 |
|---|---|
| author | Henry Tseng Henry Tseng Corey Stone Corey Stone Dédée F. Murrell Dédée F. Murrell |
| author_facet | Henry Tseng Henry Tseng Corey Stone Corey Stone Dédée F. Murrell Dédée F. Murrell |
| author_sort | Henry Tseng |
| collection | DOAJ |
| description | Autoimmune blistering diseases (AIBDs) comprise a group of rare conditions marked by autoantibodies that specifically target intercellular adhesion molecules. Despite the progress made in comprehending the disease and the increasing number of treatment options available, there is still no definitive cure for AIBDs such as pemphigus, and it continues to have a devastating impact on those affected. The challenges in achieving new approved therapies for AIBDs are complex and multifaceted. One significant obstacle was the prior lack of validated and standardized outcome measures, which are crucial for ensuring precise comparisons between new and traditional therapies. This gap in knowledge has prompted the development of minimal clinically important differences (MCIDs), which enable efficient and reliable comparison of therapeutic outcomes between trials. MCID is defined as the minimum difference in an outcome measure that indicates a clinically significant improvement/deterioration in disease severity. Additionally, MCIDs provide a patient-centered approach to evaluating treatment efficacy, by considering whether patients experience a subjective improvement in their symptoms. Therefore, this literature review will examine the derivation and significance of MCIDs for various scoring systems in AIBDs. |
| first_indexed | 2024-03-11T21:55:19Z |
| format | Article |
| id | doaj.art-fdf12b28d619400297ef9a99ab0e9cca |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T21:55:19Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-fdf12b28d619400297ef9a99ab0e9cca2023-09-26T05:07:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.12435811243581Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseasesHenry Tseng0Henry Tseng1Corey Stone2Corey Stone3Dédée F. Murrell4Dédée F. Murrell5Department of Dermatology, St. George Hospital, Sydney, NSW, AustraliaFaculty of Medicine, University of New South Wales, Sydney, NSW, AustraliaDepartment of Dermatology, St. George Hospital, Sydney, NSW, AustraliaFaculty of Medicine, University of New South Wales, Sydney, NSW, AustraliaDepartment of Dermatology, St. George Hospital, Sydney, NSW, AustraliaFaculty of Medicine, University of New South Wales, Sydney, NSW, AustraliaAutoimmune blistering diseases (AIBDs) comprise a group of rare conditions marked by autoantibodies that specifically target intercellular adhesion molecules. Despite the progress made in comprehending the disease and the increasing number of treatment options available, there is still no definitive cure for AIBDs such as pemphigus, and it continues to have a devastating impact on those affected. The challenges in achieving new approved therapies for AIBDs are complex and multifaceted. One significant obstacle was the prior lack of validated and standardized outcome measures, which are crucial for ensuring precise comparisons between new and traditional therapies. This gap in knowledge has prompted the development of minimal clinically important differences (MCIDs), which enable efficient and reliable comparison of therapeutic outcomes between trials. MCID is defined as the minimum difference in an outcome measure that indicates a clinically significant improvement/deterioration in disease severity. Additionally, MCIDs provide a patient-centered approach to evaluating treatment efficacy, by considering whether patients experience a subjective improvement in their symptoms. Therefore, this literature review will examine the derivation and significance of MCIDs for various scoring systems in AIBDs.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1243581/fullMCIDautoimmune blistering diseasespemphiguspemphigus disease area indexinvestigator global assessmentoutcome measures |
| spellingShingle | Henry Tseng Henry Tseng Corey Stone Corey Stone Dédée F. Murrell Dédée F. Murrell Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases Frontiers in Immunology MCID autoimmune blistering diseases pemphigus pemphigus disease area index investigator global assessment outcome measures |
| title | Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases |
| title_full | Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases |
| title_fullStr | Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases |
| title_full_unstemmed | Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases |
| title_short | Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases |
| title_sort | precision in treatment evaluation importance of minimal clinically important differences mcids of outcome measures for autoimmune blistering diseases |
| topic | MCID autoimmune blistering diseases pemphigus pemphigus disease area index investigator global assessment outcome measures |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1243581/full |
| work_keys_str_mv | AT henrytseng precisionintreatmentevaluationimportanceofminimalclinicallyimportantdifferencesmcidsofoutcomemeasuresforautoimmuneblisteringdiseases AT henrytseng precisionintreatmentevaluationimportanceofminimalclinicallyimportantdifferencesmcidsofoutcomemeasuresforautoimmuneblisteringdiseases AT coreystone precisionintreatmentevaluationimportanceofminimalclinicallyimportantdifferencesmcidsofoutcomemeasuresforautoimmuneblisteringdiseases AT coreystone precisionintreatmentevaluationimportanceofminimalclinicallyimportantdifferencesmcidsofoutcomemeasuresforautoimmuneblisteringdiseases AT dedeefmurrell precisionintreatmentevaluationimportanceofminimalclinicallyimportantdifferencesmcidsofoutcomemeasuresforautoimmuneblisteringdiseases AT dedeefmurrell precisionintreatmentevaluationimportanceofminimalclinicallyimportantdifferencesmcidsofoutcomemeasuresforautoimmuneblisteringdiseases |